Home > Article > Suprachoroidal Injection of Triamcinolone— Review of a Novel Treatment for Macular Edema due to Noninfectious Uveitis
Uveitis and Ocular Immunology
Read Time: < 1 min

Suprachoroidal Injection of Triamcinolone— Review of a Novel Treatment for Macular Edema due to Noninfectious Uveitis

Published Online: December 23rd 2020 US Ophthalmic Review. 2020;13(2):Online ahead of journal publication
Authors: Kenneth W Price, Thomas A Albini, Steven Yeh
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Macular edema is the most frequent cause of visual deterioration in noninfectious uveitis. The treatment of noninfectious uveitis with associated macular edema commonly includes systemic or locally administered corticosteroids, with long-term use limited by significant side effects. The need for a treatment with an improved safety profile has driven the development of a novel ophthalmic therapy a proprietary triamcinolone acetonide suspension (CLS-TA) administered in the suprachoroidal space (XIPERE™; Clearside Biomedical, Alpharetta, GA, USA). Suprachoroidal delivery of corticosteroids allows higher steroid concentration in the posterior segment and decreases the risk of other adverse ocular effects. Recent results from the PEACHTREE trial, a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow-up lasting 24 weeks, show the significant improvement in visual acuity and reduction in central subfield thickness all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.

Keywords

Suprachoroidal injection, macular edema, uveitis, steroid

Article:

**This manuscript has been accepted for publication, but may be subject to minor changes during the production process.**

Article Information:
Disclosure

Dr Price has no financial disclosures to declare. Dr. Albini is a Consultant for Clearside Biomedical. Dr. Yeh is a Consultant for Clearside Biomedical, Bausch and Lomb, and Santen, Inc.

Compliance With Ethics

This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review

Authorship

The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Correspondence

Steven Yeh, 1365 Clifton Rd. Bldg B T401A, Atlanta, GA, 30322, USA. E: steven.yeh@emory.edu

Support

This project was supported by the National Eye Institute/ National Institutes of Health core grant P30-EY06360 (Department of Ophthalmology, Emory University School of Medicine) and R01 EY029594 (Dr. Yeh). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was also supported an unrestricted departmental grant from Research to Prevent Blindness, Inc. to the Emory Eye Center, Emory University School of Medicine.

Open Access

This article is freely accessible at touchOPHTHALMOLOGY.com. © Touch Medical Media 2020

Received

2020-07-29

Further Resources

Share this Article
Related Content In Uveitis and Ocular Immunology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar